ReviewJournal of healthcare engineering2021
Design of the Internet plus Drug Circulation Business Model Based on Value Chain.
Review in Journal of healthcare engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Retracted: Design of the Internet plus Drug Circulation Business Model Based on Value Chain.Journal of healthcare engineering · 2023Article
- A Convolutional Neural Network-Based Model for Supply Chain Financial Risk Early Warning.Computational intelligence and neuroscience · 2022Article
- Impact of Factors of Online Deceptive Reviews on Customer Purchase Decision Based on Machine Learning.Journal of healthcare engineering · 2021Article
Corrections and comments
- Retraction · 2023-05-24Concerns/Issues about Data · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the continuous development of computers and the Internet, all industries in China have brought new opportunities for change, and pharmaceutical e-commerce has also shown great potential for development. With the call and encouragement of national policies, the "Internet + drug distribution" business model has shown great potential to replace the traditional drug distribution model in the near future due to its advantages of shortening the transaction process and reducing the cost of enterprises. This paper presents a literature review on theories related to "Internet + drug distribution," value chain and business model at home and abroad, and focuses on how traditional drug distribution enterprises should adopt the "Internet + drug distribution" model when the country is vigorously promoting it. The study focuses on how traditional pharmaceutical distribution companies should innovate their business models from the perspective of value chain to seek better development. By comparing the business models before and after the innovation, the new business model of "Internet + drug distribution" can help enterprises establish diversified value propositions, increase revenue channels, and reduce operating costs. At the same time, it can integrate and innovate the internal and external value chains of enterprises, so that traditional pharmaceutical distribution enterprises can further enhance their competitiveness and expand their market share. This thesis can enrich the application of value chain and business model theories in the field of "Internet + drug distribution," and it is hoped that the model experience developed in this thesis can be used as a reference for similar enterprises in their transformation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.